Are These 4 Robinhood Penny Stocks Ready to Take Flight?
Robinhood penny stocks have become some of the most trending stocks to watch in the past few months. There are a few reasons why this is the case. For one, there are hundreds of options when it comes to finding penny stocks on Robinhood.
Because the term ‘penny stocks’ itself, applies to any stocks under $5, you can see the options are aplenty. The second reason is that Robinhood is one of the most accessible trading platforms out there. With zero commission trades and an easy-to-use platform, Robinhood essentially democratized trading when it first became popular.
Now it’s worth noting that the brokerage has its ups and downs. It has been known to halt trading in times of massively heightened volume, and this has not pleased investors. However, we can’t deny that the existence of Robinhood has fundamentally changed trading penny stocks and blue chips as well.
[Read More] 4 Penny Stocks To Watch As Dogecoin, Bitcoin & Cryptocurrency SurgeSo, because of this, many investors have turned to Robinhood to buy and sell stocks under $5 because of its $0 commission fees. And while many brokerages have followed suit, Robinhood remains one of the most popular among under 35 investors. So with all of this in mind, let’s take look at four of the best penny stocks to watch on Robinhood right now.
4 Robinhood Penny Stocks to Watch
- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP)
- Meten EdtechX Education Group Ltd. (NASDAQ: METX)
- Minerva Neurosciences Inc. (NASDAQ: NERV)
- Akebia Therapeutics Inc. (NASDAQ: AKBA)
1. Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP)
Corbus Pharmaceuticals Holdings Inc. is a leading biotech and marijuana stock that has performed quite well in the past few weeks. You may be wondering, what does Corbus Pharmaceuticals Holdings do?
This company is focused on the development and commercialization of novel therapeutics that target autoimmune disorders, fibrosis, and cancer. These endocannabinoid system products include its lead candidate lenabasum, which is a cannabinoid receptor type 2 medicine in Phase III trials.
Corbus has plans to present at three upcoming conferences. These include the 2021 RBC Capital Markets Global Healthcare Conference, Oppenheimer Rare & Orphan Disease Summit, and the Jefferies Virtual Global Healthcare Conference. Ahead of these conferences, CRBP stock is up 24% on May 14th. It seems like investors have a bullish sentiment about CRBP ahead of its upcoming announcements.
Just last month the company also announced the completion of enrollment for its Phase 2 study of Lenabasum for treating systemic lupus erythematosus. The study, sponsored and funded by the National Institute of Allergy and Infectious Diseases, will take place over 16 weeks. Patients will be given either 20 mg twice daily, 20 mg once daily, 5mg twice daily, or placebo.
As you can see, Corbus has a lot in its pipeline. This could make CRBP a more attractive option to long-term and short-term penny stock investors. This penny stock has experienced many ups and downs in 2021, which illustrates how volatile it is.
With prices moving frequently, investors should remember that things can often get risky. But if you are careful in how you invest, this risk can be mitigated. With this in mind, is CRBP on your list of penny stocks to watch?
2. Meten EdtechX Education Group Ltd. (NASDAQ: METX)
Meten EdtechX Education Group Ltd. is a tech penny stock that provides English language training services in China. The company provides its services in four different ways. This includes general adult English training, overseas training services, online English training, and junior English training. Currently, it operates 105 learning centers in 28 cities and 15 provinces in China.
The company intends on reporting its first-quarter financial results on Thursday, May 20th. This does not mean there aren’t other updates that have come from Meten. The company did report on May 12th that it has achieved positive cash flow in March 2021. This operating cash flow was generated because of increasing gross billing generated by its offline learning centers since it has recovered operation after the pandemic.
It intends on continuing this by closing poorly performing stores and letting go of employees as well as increasing its sales through the optimization of its incentive plan. It also plans on increasing the efficiency of its marketing. In the first quarter of 2021, Meten saw a 485% increase in gross billing and a 483% increase in student enrollment of its junior English language training business. The company expects to grow 82% in gross billing this year.
[Read More] Best Penny Stocks To Buy According To Analysts, 1 With 95% TargetIf you’ve been finding penny stocks to watch recently, you will know that many have gotten involved in blockchain technology. While Meten is not a pure play blockchain penny stock, it is working to get involved. The company is planning to make full use of blockchain technology with its offerings. The company has placed a focus on accelerating technological innovation and digital transformation of online education via blockchain.
It would be able to give students transparent, credible, and tamper-proof digital certificates to mitigate academic dishonesty. This could turn out to be widely used in all types of education sections. When taking exams, for example, the company could ensure that no cheating occurs using its digital platform. With all of these advancements in mind, is METX on your penny stock watchlist?
3. Minerva Neurosciences Inc. (NASDAQ: NERV)
The biotech company, Minerva Neurosciences Inc., focuses on developing and commercializing central nervous system disease treatment products. Its lead product is roluperidone which is a compound that is in Phase III trials to treat schizophrenia. It is working on treatments for Parkinson’s as well.
On May 12th the company reported its 2021 financial results and business updates. Its results for its schizophrenia trial are very positive. It is seeing a continuous improvement in negative symptoms, continuous improvement in personal and social performance, and has a favorable safety profile.
“The results of the open-label extension of the phase 3 trial with roluperidone provide additional support for the continued development of this agent, particularly in an environment with a continuing significant unmet medical need for schizophrenia treatments with novel mechanisms of action.”
Dr. Remy Luthringer, Executive Chairman and CEO of Minerva
For its financial results, its net less fell a lot year over year from $12.2 million to $8.8 million. After this promising schizophrenia study data was released, the company’s stock price has soared. NERV stock is up 5.5% on May 14th, and up about 25% in the last 5 days.
This has placed a bullish sentiment on Minerva that has caused its volume to be about 1.2 million higher than average. Its new encouraging data should support a New Drug Application to the FDA following the completion of a bioequivalence study. With all of this information in mind, will you invest in NERV for your penny stock watchlist?
4. Akebia Therapeutics Inc. (NASDAQ: AKBA)
Akebia Therapeutics Inc. focuses on the development and commercialization of renal therapeutics. These are in use to treat patients that have a range of kidney diseases. One of its main products is vadadustat, which is an oral therapy in Phase III development to treat anemia caused by chronic kidney disease. It also has Auryxia which is aferric citrate-based medicine used to control serum phosphorus levels in adults with CKD on dialysis.
When May 10th came around, Akebia released its first-quarter 2021 financial results and highlighted its recent company milestones. It submitted a New Drug Application or NDA to the U.S. Food and Drug Administration for Vadadustat during this period.
“Akebia is off to a great start in 2021, building positive momentum with solid execution on strategic priorities that set the stage for an exciting year. Most importantly, we submitted the vadadustat NDA to the FDA, a significant milestone for Akebia and our partner, Otsuka Pharmaceutical Co. Ltd.
We are also very proud that the New England Journal of Medicine recently published the results from both INNO2VATE and PRO2TECT, the global Phase 3 programs for vadadustat.”
The CEO of Akebia, John P. Butler
In regards to its financials, its total revenue fell year over year because of lower collaboration revenue. This is because of the completion of two of its Phase 3 clinical programs. For the same reason, its R&D expenses fell year over year. Its net loss also increased for similar reasons.
The company believes that despite the negative impact of COVID-19 on its business, it has favorable odds for the future. The company is still being cautious with the pandemic going on, but it states that it could have product revenue growth in 2021. AKBA stock has increased in value by about 17% since this report was released.
Does this mean that AKBA will continue to grow in 2021? This is uncertain, but we will know more about where the company stands when its next update is released. Will AKBA stock make your list of penny stocks to watch this month?
Are These Penny Stocks on Robinhood Worth It?
Finding the hottest penny stocks on Robinhood can be a challenge for some. If you don’t know what you’re looking for, it can be easy to get lost and end up in the red. However, with a trading education and a dedication to learning as much as you can, buying and selling penny stocks on Robinhood can be easy.
[Read More] How to Buy Penny Stocks In 2021In addition, investors should use the tools at their disposal to figure out if certain stocks align with their portfolios and investing styles. Considering all of this, are these Robinhood penny stocks worth it?
